Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows, but more slowly than its trailing trend

Q2 FY2026 EBITDA of $54.57M rose 93.9% year over year, behind the +117.6% change in trailing-twelve-month EBITDA. Sequentially, it rose 9.7% from the prior quarter.

Context

  • EBITDA amounted to 45.1% of revenue in FY2025, up 31.6 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $178.47M (+39.7%) for the fiscal year ending Dec 2026, a slowdown from the +302.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$54.57M+9.7% QoQ
Last fiscal yearDec 2025
$127.76M+302.7% YoY
LTMJun 2026
$188.22M+117.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.9%+17.7%-76.2 pp
1 year+302.7%+39.7%-263.0 pp
3-year CAGR—+23.0%—
5-year CAGR+22.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
127.76M USD
Year-over-year change
+302.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 EBITDA of $188.22M is the highest of the 10 companies compared; the peer median is -$178.45M.
  • Its year-over-year change of +117.6% is the highest of 9, against a peer median of -46.2%.
  • EBITDA amounts to 60.4% of revenue for AUPH, versus a peer median of 2879.6%.
AUPH Competitors Peer median
EBITDA for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$188.22M +117.6%—60.4%
ATTOAttovia Therapeutics, Inc.FY2025-$66.36M -60.9%—4915.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M -31.5%—843.9%
EVMNEvommune, Inc.LTM Mar 2026-$74.62M ——746.2%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.03M -325.2%——
TRAXFirst Tracks Biotherapeutics IncFY2025-$178.45M +0.1%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$245.81M -69.1%——
VERAVera Therapeutics, Inc.LTM Jun 2026-$393.82M -87.1%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$442.87M -9.5%—5986.3%
BHVNBiohaven Ltd.LTM Jun 2026-$574.94M +24.1%——
Peer median (excluding AUPH) -$178.45M-46.2%—2879.6%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.61M134.03M175.51M235.13M283.06M
Cost of Revenue1.09M5.66M14.15M28.25M32.67M
Gross Profit44.51M128.37M161.37M206.89M250.39M
Gross Margin97.6%95.8%91.9%88.0%88.5%
Research & Development51.14M44.99M49.64M20.79M32.51M
Selling, General & Admin171.44M196.37M195.04M172.03M101.79M
Operating Expenses225.25M239.84M253.06M211.57M145.48M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
EBITDA(177.45M)(103.65M)(63.05M)31.73M127.76M
EBITDA Margin-389.1%-77.3%-35.9%13.5%45.1%
Operating Income(180.74M)(111.47M)(91.69M)(4.69M)104.91M
Operating Margin-396.3%-83.2%-52.2%-2.0%37.1%
Interest Income529K5.12M17M16.97M13.57M
Interest Expense002.78M4.84M4.33M
Other Income / Expenses529K5.12M14.22M12.14M9.24M
Income Before Tax(180.21M)(106.35M)(77.47M)7.45M114.16M
Pre-Tax Margin-395.1%-79.3%-44.1%3.2%40.3%
Income Tax Expense760K1.83M551K1.7M(173.05M)
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (Basic)(1.40)(0.76)(0.54)0.042.14
EPS (Diluted)(1.40)(0.76)(0.54)0.042.07
Weighted Avg Shares129.37M141.92M143.24M143.06M134.37M
Weighted Avg Shares (Diluted)129.37M141.92M143.24M146.19M138.7M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.